| If you would like to be alerted when a new press release is added please register with the Alert Service. |
| Interim Results For The Six Months Ended 31 March 2008 |
| 19/06/2008 |
|
GW Pharmaceuticals plc (AIM: GWP), the developer and manufacturer of a range of new cannabinoid medicines, including Sativex®, announces its interim results for the six months ended 31 March 2008. An on-demand webcast with synchronised PowerPoint is available here. Access the webcast. |
| Notification of Results |
| 05/06/2008 |
|
GW Pharmaceuticals plc (AIM: GWP) will be announcing its interim financial results for the six months ended 31 March 2008 on Thursday 19 June. |
| Catalan Government Reports Positive Outcome of Sativex Access Programme |
| 09/04/2008 |
|
GW Pharmaceuticals plc (GWP:AIM) announces that the Government of Catalonia in Spain is today publishing positive results of its pilot programme to evaluate Sativex® as a treatment for high need patients suffering from a range of medical conditions. |
| Phase III MS Neuropathic Pain Trial Preliminary Results |
| 08/04/2008 |
|
GW Pharmaceuticals plc (AIM: GWP) announces preliminary results of a Phase III double-blind randomised placebo-controlled study of Sativex® in 339 patients with central neuropathic pain due to Multiple Sclerosis (MS), who have achieved inadequate pain relief with existing therapies.
A conference call for analysts was held at 8.30am BST on 8 April 2008. A recording of this call, with embedded PowerPoint presentation, is available. Access the on-demand webcast. |
| AGM Statement |
| 18/03/2008 |
|
Dr. Geoffrey Guy, Chairman of GW Pharmaceuticals plc, will make the following comments at today’s Annual General Meeting: |
| Appointment of Company Secretary |
| 05/03/2008 |
|
GW Pharmaceuticals plc announces that Adam George BSc, ACA has been appointed as Company Secretary and Financial Controller. |
| Preliminary Results for the Year Ended 30 September 2007 |
| 22/01/2008 |
|
GW Pharmaceuticals plc (AIM: GWP), the developer and manufacturer of a range of new cannabinoid medicines including Sativex®, announces its preliminary results for the year ended 30 September
2007. An on-demand audio webcast with synchronised PowerPoint is available. Access the webcast. |
| Highly Promising Results for New GW Cannabinoid Treatments for Diabetes and Related Metabolic Disorders |
| 22/01/2008 |
|
GW Pharmaceuticals plc (AIM: GWP) announces that it has generated highly promising results in both pre-clinical pharmacology studies and a Phase I trial of a new potential cannabinoid treatment for type 2 diabetes and related metabolic disorders. |
| GW Welcomes Move by UK Regulator to Provide More Information for Sativex® Prescribers |
| 13/12/2007 |
|
GW Pharmaceuticals plc (AIM: GWP) welcomes the publication today by the UK regulator, the Medicines & Healthcare products Regulatory Agency (MHRA) of a Public Information Report on Sativex®, GW’s cannabinoid spray medicine. In addition to this release a Q&A document is available here. |
| GW Commences Sativex® Phase III Clinical Trial in MS Spasticity |
| 03/12/2007 |
|
GW Pharmaceuticals plc (AIM: GWP) today announces that it has started a new Phase III trial of Sativex® in Multiple Sclerosis (MS) Spasticity. This trial is designed to resolve the outstanding issue arising from the recent European regulatory submission and to provide the basis for regulatory approval of Sativex in the indication of MS Spasticity. The study aims to report headline results towards the end of 2008. |
| Sativex® Commences US Phase II/III Clinical Trial in Cancer Pain |
| 26/11/2007 |
|
GW Pharmaceuticals plc (AIM: GWP) and Otsuka Pharmaceutical Co., Ltd. today announced that the first US Phase II/III dose-ranging trial has been initiated to evaluate the efficacy and safety of Sativex® in the treatment of pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy. |
| New Published Study Shows Sativex® Successfully Treats Neuropathic Pain |
| 12/11/2007 |
|
GW Pharmaceuticals plc (AIM: GWP) today announces that The International Association of the Study of Pain has published online the results of a study in its official journal Pain, showing that Sativex® successfully treats peripheral neuropathic pain1. |
| New Published Study Shows Sativex® Provides Effective Long Term Treatment of MS Neuropathic Pain |
| 17/10/2007 |
|
GW Pharmaceuticals plc (AIM: GWP) today announces that the Journal of Clinical Therapeutics has published the results of a study which show that Sativex® provides effective long term treatment of central neuropathic pain in Multiple Sclerosis (MS) and that these benefits are obtained without any evidence of tolerance (increase in dose) to the medicinei. |
| Sativex® Phase III Trial in MS Neuropathic Pain Completes Patient Recruitment |
| 30/08/2007 |
|
GW Pharmaceuticals plc (AIM: GWP) announces that patient recruitment is now complete in its pivotal Phase III trial in people with multiple sclerosis (MS) suffering from central neuropathic pain. |
| Health Canada Approves Sativex® For Cancer Pain |
| 07/08/2007 |
|
GW Pharmaceuticals plc (AIM: GWP) and Bayer Inc., a subsidiary of Bayer AG, today announce that Health Canada has approved Sativex®, a cannabis derived pharmaceutical treatment, as adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain. Sativex, the only pharmaceutical product derived from components of the cannabis plant, is administered through a spray into the patient’s mouth. |
| GW EU Regulatory Withdrawal |
| 20/07/2007 |
|
GW Pharmaceuticals plc (AIM: GWP) announces that it has chosen to withdraw its current regulatory application for Sativex in Europe and that it expects to resubmit an application for approval in 2008. This follows constructive and detailed discussions with regulatory authorities in which they have provided a clear path to approval for Sativex in the treatment of MS Spasticity. |
| GW and Otsuka Enter Into Global Cannabinoid Research Collaboration |
| 09/07/2007 |
|
GW Pharmaceuticals plc and Otsuka Pharmaceutical Co., Ltd today announce a major long term strategic cannabis alliance. An exclusive licence and development agreement has been signed for Sativex® in the United Stated and the companies are in detailed discussions with a view to entering into a cannabinoid research collaboration in the field of Central Nervous System (CNS) disorders and cancer treatments to research, develop and commercialise a range of other early stage cannabinoid product opportunities. |
| Interim Results For The Six Months Ended 31 March 2007 |
| 19/06/2007 |
|
GW Pharmaceuticals plc (AIM: GWP), the developer and manufacturer of a range of new cannabinoid medicines, including Sativex®, announces its interim results for the six months ended 31 March 2007. |
| Sativex® receives Qualifying Notice for approval in Canada for the relief of Cancer Pain |
| 19/06/2007 |
|
GW Pharmaceuticals plc (AIM: GWP) and Bayer HealthCare Pharmaceuticals announce that Health Canada, the Canadian regulatory agency, has issued a Qualifying Notice for the approval of Sativex® in the relief of cancer pain. |
| GW Commences Phase I Study of THCV, a Potential Treatment for Obesity and Related Metabolic Disorders |
| 04/06/2007 |
|
GW Commences Phase I Study of THCV, a Potential Treatment for Obesity and Related Metabolic Disorders |
| GW and Otsuka Receive Hart-Scott-Rodino Clearance for Sativex® US License Agreement |
| 22/03/2007 |
|
GW Pharmaceuticals plc (AIM: GWP) and Otsuka Pharmaceutical Co. Ltd today announce that they have each received early termination by the United States Federal Trade Commission and the Antitrust Division of the United States Department of Justice of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to the development and license agreement announced on 14 February 2007 granting Otsuka exclusive rights to develop and market Sativex®, GW's lead product, in the United States. With the grant of HSR clearance, GW and Otsuka have now received the approval of the U.S. antitrust authorities necessary to close the transaction. |
| GW Pharmaceuticals plc announces changes to Board of Directors |
| 15/03/2007 |
|
GW Pharmaceuticals plc (AIM: GWP) today announces the appointment of Mr Richard Forrest as a non-executive director. Mr Forrest replaces Mr David Morrison who is standing down from the Board with effect from today. |
| Phase III Sativex® Data Published in Leading Neurology Journal |
| 28/02/2007 |
|
GW Pharmaceuticals plc (AIM: GWP) a leading neurology journal, The European Journal of Neurology, today reports a study showing that Sativex significantly reduces intractable spasticity (spasms and stiffness) in people with Multiple Sclerosis (MS). |
| GW and Otsuka Announce Major Long Term Strategic Cannabinoid Alliance |
| 14/02/2007 |
|
GW Pharmaceuticals plc (AIM: GWP) and Otsuka Pharmaceutical Co., Ltd. today announce that they have entered into a major long term strategic cannabinoid alliance. |
| Preliminary Results for the Year Ended 30 September 2006 |
| 30/01/2007 |
|
GW Pharmaceuticals plc (AIM: GWP), the developer and manufacturer of a range of new cannabinoid medicines, including Sativex®, announces its preliminary results for the year ended 30 September 2006. |
| GW strengthens board with appointment of James Noble |
| 26/01/2007 |
|
GW Pharmaceuticals plc (AIM: GWP) is pleased to announce the appointment of James Noble as an independent non-executive director with immediate effect. James has also been nominated as senior independent director, and will sit on the Remuneration Committee as well as the Audit Committee, which he has agreed to Chair in due course. |
| Results of Sativex® Phase III Neuropathic Pain Trials Demonstrate Benefits for High Need Treatment-Resistant Patients |
| 15/01/2007 |
|
GW Pharmaceuticals plc (“GW”) today announces preliminary results of two Phase III studies of Sativex®, its cannabinoid spray medicine, in peripheral neuropathic pain. These studies are part of a programme to generate data for the future expansion of the use of Sativex in Europe beyond Multiple Sclerosis (MS) into other pain conditions. |
| GW Files Sativex® Regulatory Submission in Canada for Cancer Pain |
| 19/10/2006 |
|
GW Pharmaceuticals plc (AIM: GWP) (“GW” or “the Company”) and Bayer HealthCare, Pharmaceuticals Division - Canada (“Bayer”) announce that GW has submitted a regulatory application in Canada for Sativex® to seek approval for a new indication for the treatment of pain in patients with advanced cancer that has not been adequately relieved by opioid medications. |
| Sativex® Data Presented at ECTRIMS European Multiple Sclerosis Congress |
| 03/10/2006 |
|
GW Pharmaceuticals plc (AIM: GWP) announces today that results from two Phase III studies of Sativex ® were presented at Europe's leading multiple sclerosis (MS) conference, the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis ( ECTRIMS), which took place in Madrid, Spain, from 27 - 30 September. The outcome of the studies in spasticity and bladder dysfunction, both symptoms of MS, were first reported by GW earlier this year. |
| GW Files Sativex® for Approval in Selected European Countries for MS Spasticity |
| 05/09/2006 |
|
GW Pharmaceuticals plc (AIM: GWP) (“GW” or “the Company”) today announces that it has filed a regulatory submission in selected European countries for Sativex®, its cannabinoid spray medicine. The filing is for the symptomatic relief of spasticity in people with multiple sclerosis (MS), a patient group with a significant unmet medical need. |
| Start of Second Phase III Trial in MS Neuropathic Pain |
| 09/08/2006 |
|
GW Pharmaceuticals plc (AIM: GWP) announces the start of a second pivotal Phase III trial in people with multiple sclerosis (MS) suffering from central neuropathic pain. The first patient has now been enrolled in the study. |
| Interim Results For The Six Months Ended 31 March 2006 |
| 20/06/2006 |
|
GW Pharmaceuticals plc (AIM: GWP), the developer and manufacturer of a range of new medicines based on cannabis and other controlled drugs, announces its interim results for the six months ended 31 March 2006. GW today is also hosting a research and development (R&D) day for analysts and investors. |
| Appointment of Adviser |
| 16/05/2006 |
|
GW Pharmaceuticals plc (AIM: GWP) is today pleased to announce the appointment of Investec Bank (UK) Limited as Nominated Adviser and Broker to the Company with immediate effect. |
| Preliminary Results from Sativex® Phase III Multiple Sclerosis spasticity study |
| 17/03/2006 |
|
GW Pharmaceuticals plc (AIM: GWP) today announces preliminary results from a Phase III study of Sativex® in the relief of spasticity in people with Multiple Sclerosis (MS). |
| Changes to Non-Executive Directors |
| 10/02/2006 |
|
GW Pharmaceuticals today announces the appointment of Mr David Morrison as a non-executive director with immediate effect. Mr Morrison replaces Mr Peter Mountford, who today resigns as a non-executive director. |
| Preliminary Results for the Year Ended 30 September 2005 |
| 19/01/2006 |
|
GW Pharmaceuticals plc, the company which develops and manufactures a range of new medicines based on cannabis and other controlled drugs, announces its preliminary results for the year ended 30 September 2005. |
| FDA Accepts Investigational New Drug (IND) Application For Sativex® |
| 04/01/2006 |
|
GW Pharmaceuticals (AiM:GWP) today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) Application for Sativex®, a cannabis-derived, oro-mucosal spray composed primarily of tetrahydrocannabinol (THC) and cannabidiol (CBD), a non-psychoactive cannabinoid, for the treatment of pain in patients with advanced cancer that has not been adequately relieved by opioid medications. |
| GW Raises $15m (£8.6m) in US Placing |
| 04/01/2006 |
|
GW Pharmaceuticals plc (AiM:GWP) today announces that it has signed an agreement with a United States-based institutional investor to raise $15 million (£8.6 million) before expenses through a placing for cash of 6,165,978 new GW ordinary shares at 139.61 pence per share. |
| Statement In Response To The Verdict Of The Inquest Into The Death Of Mrs Rene Anderson |
| 16/12/2005 |
|
During the course of this week, an inquest has taken place in Sheffield into the death of Mrs Rene Anderson. Mrs Anderson, a 69 year old diabetic, died in March 2004. |
| GW and Almirall Announce European Development and Marketing Agreement for Sativex® |
| 12/12/2005 |
|
GW and Almirall Prodesfarma, S.A. (“Almirall”) announce that they have entered into an exclusive agreement for Almirall to market Sativex® in Europe (excluding the UK). |
| UK Named Patient Prescribing for Sativex® |
| 15/11/2005 |
|
GW announces that it has been informed by the Home Office that the Drugs Minister, Paul Goggins, has confirmed that Sativex® oromucosal spray, its cannabis-based medicine, may be imported from Canada to satisfy its prescription to individual patients in the UK as an unlicensed medicine. |
| Rheumatology Journal Publishes Positive Sativex® Study in Rheumatoid Arthritis |
| 09/11/2005 |
|
Rheumatology, the official monthly journal of the British Society of Rheumatology (BSR), today announces the publication of the first study to use a cannabis-based medicine (CBM) for treating rheumatoid arthritis. The CBM used in the study is Sativex® oromucosal spray which is standardised for composition, formulation and dose and was developed by GW. |
| Sativex® to be supplied by Catalonian Government to 600 patients in Spain |
| 08/11/2005 |
|
GW Pharmaceuticals is today pleased to announce that it has reached agreement with the Health Department of The Regional Government of Catalonia in Spain to supply Sativex® oromucosal spray, its cannabis-based medicine, to 600 patients suffering from Multiple Sclerosis and a number of other conditions under a compassionate access programme. |
| Sativex®, a Cannabis-Based Medicine, Significantly Reduces Central Neuropathic Pain in People with Multiple Sclerosis |
| 27/09/2005 |
|
The cannabis based medicine, Sativex®, is effective in reducing central neuropathic pain and sleep disturbance in people with Multiple Sclerosis (MS) in a UK study published today in the medical journal, Neurology |
| Interim Results For The Six Months Ended 31 March 2005 |
| 20/06/2005 |
|
GW Pharmaceuticals plc, the company which develops and manufactures a range of new medicines based on cannabis and other controlled drugs, announces its interim results for the six months ended 31 March 2005. |
| Sativex® Launched in Canadian Market by Bayer HealthCare |
| 20/06/2005 |
|
GW is pleased to announce that, following the receipt of regulatory approval from Health Canada, Sativex is now available by prescription through Canadian pharmacies as an adjunctive treatment for symptomatic relief of neuropathic pain in adults with multiple sclerosis (MS). |
| UK Regulatory Update Medicines Commission Confirms Further Clinical Efficacy Data Required |
| 10/06/2005 |
|
In December 2004, GW announced that the Committee on Safety of Medicines (CSM), an advisory body to the UK regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA), had advised that a further clinical study in Multiple Sclerosis (MS) Spasticity would be required prior to the grant of a UK product licence for Sativex®. |
| Statement Re: Media Comment |
| 06/06/2005 |
|
GW notes recent media comment. |
| Misleading US Advertisement - GW Response |
| 19/05/2005 |
|
If you are in the United States and are accessing this web page in response to a US advertisement funded by Common Sense for Drug Policy, please note that this advertisement is not endorsed by GW Pharmaceuticals. Indeed, GW disputes and rejects the contents of the advertisement. |
| GW Announces Amendments to its Sativex Marketing Agreement |
| 11/05/2005 |
|
GW and Bayer Healthcare AG announce certain amendments to their marketing agreement for Sativex in the UK and Canada. The amendments have been made in light of the recent regulatory approval of Sativex in Canada, and reflect the fact that approval was granted in Canada before the UK, and not vice versa as was envisaged at the time that the marketing agreement was entered into in May 2003. |
| GW Announces Regulatory Approval of Sativex® in Canada |
| 19/04/2005 |
|
GW announces that Sativex® has been granted regulatory approval in Canada for the symptomatic relief of neuropathic pain in multiple sclerosis. |
| Appointment of Dr Stephen Wright as Director |
| 23/03/2005 |
|
GW is pleased to announce the promotion of Dr Stephen Wright to GW’s Board of Directors with immediate effect. |
| GW Appoints Senior US Experts to Support US Market Entry |
| 28/02/2005 |
|
US Founder Investors increase stake with approx $5m additional investment |
| Preliminary Results for the Year Ended 30 September 2004 |
| 19/01/2005 |
|
GW Pharmaceuticals announces its Preliminary Results for the year ended 30 September 2004 |
| GW Announces Positive Preliminary Results with its Cannabis-based Medicine (Sativex®) in Phase III Cancer Pain Trial |
| 19/01/2005 |
|
GW Pharmaceuticals announces positive preliminary results in a Phase III clinical trial with Sativex® in 177 patients with severe cancer pain. |
| GW receives Qualifying Notice for approval in Canada for Sativex® |
| 21/12/2004 |
|
GW Pharmaceuticals announces that Health Canada, the Canadian regulatory authority, has issued a Qualifying Notice for the approval of Sativex®, a cannabis-based medicinal extract product. |
| GW Conference Call with Pharmaceuticals Analysts |
| 03/12/2004 |
|
GW hosted a conference call with pharmaceuticals analysts today. |
| Regulatory Update - UK and Canada |
| 03/12/2004 |
|
GW is today providing an update on the progress of its regulatory filings for Sativex in the UK and Canada. |
| GW Announces Positive Preliminary Results with its Cannabis-based Medicine (Sativex®) in Phase III Multiple Sclerosis Trial |
| 21/06/2004 |
|
GW Pharmaceuticals announces positive preliminary results in a Phase III clinical trial to assess the effects of Sativex® on spasticity in 189 patients with Multiple Sclerosis (MS). |
| Interim Results For The Six Months Ended 31 March 2004 |
| 21/06/2004 |
|
GW Pharmaceuticals plc, the company which is developing a range of new medicines based on cannabis and other controlled drugs, announces its interim results for the six months ended 31 March 2004. |
| GW Announces Positive Preliminary Results with its Cannabis Medicine in Phase III Neuropathic Pain Trial |
| 15/06/2004 |
|
GW Pharmaceuticals announces positive preliminary results in a Phase III clinical trial with Sativex® in 125 patients with neuropathic (nerve damage) pain. |
| GW Announces Positive Preliminary Results with its Cannabis-based Medicine in Phase II Rheumatoid Arthritis Pain Trial |
| 09/06/2004 |
|
GW Pharmaceuticals plc announces positive preliminary results in a Phase II clinical trial in patients with pain caused by Rheumatoid Arthritis. |
| GW submits New Drug Submission for Sativex®, Cannabis-Based Medicine, to Health Canada |
| 11/05/2004 |
|
GW Pharmaceuticals plc (“GW” or “the Company”) and Bayer HealthCare, Pharmaceuticals Division - Canada (“Bayer”) announce that GW has submitted a New Drug Submission for Sativex®, a cannabis-based medicinal extract product, to Health Canada. |
| Sativex® Regulatory Update |
| 30/04/2004 |
|
On 21 January 2004, GW announced that it expected the regulatory assessment process for Sativex to be completed during the second quarter of 2004. |
| Result of AGM |
| 02/03/2004 |
|
GW Pharmaceuticals is pleased to announce that, at the Annual General Meeting of
the Company held earlier today, all of the resolutions proposed were duly passed.
|
| Preliminary Results for the Year Ended 30 September 2003 |
| 21/01/2004 |
|
GW Pharmaceuticals plc, the company which develops a range of new medicines based on cannabis and other controlled drugs, announces its preliminary results for the year ended 30 September 2003. |
| Appointment of Advisers |
| 14/01/2004 |
|
GW announces that it has appointed N M Rothschild & Sons as its financial adviser and Hoare Govett Limited as its Nominated Adviser and broker with immediate effect. |
| GW and Bayer Extend Marketing Agreement For Sativex to Canadian Market |
| 06/11/2003 |
|
GW Pharmaceuticals plc (“GW”) and Bayer Healthcare AG (“Bayer”) announce that they have extended their marketing agreement for Sativex®, GW’s cannabis-based medicinal extract product, to the Canadian market. |
| GW Raises £20 Million to Accelerate Development Programme |
| 27/06/2003 |
|
GW is pleased to announce that it is raising approximately £20 million before expenses through a placing for cash of 9,904,395 new GW ordinary shares at 200 pence per share. |
| Interim Results For The Six Months To 31 March 2003 |
| 19/06/2003 |
|
GW Pharmaceuticals plc, the company licensed by the UK Home Office to work with cannabis and a range of controlled drugs for medical research purposes, announces its interim results for the six months ended 31 March 2003. |
| GW and Bayer Announce Marketing Agreement on Pioneering New Cannabis-based Treatment |
| 21/05/2003 |
|
GW Pharmaceuticals plc (“GW”) and Bayer AG (“Bayer”) have entered into an exclusive marketing agreement for GW’s cannabis-based medicinal extract product, to be marketed under the Sativex® brand name. |
| Appointment of Non-Executive Director |
| 16/04/2003 |
|
GW announces the appointment of Hans Schram as a non-executive director with immediate effect. Mr Schram has over 20 years experience in global pharmaceutical business development and marketing. |
| Submission of Regulatory Application to MCA |
| 31/03/2003 |
|
GW announces that the regulatory dossier for the Company’s first cannabis-based prescription medicine has been submitted to the UK Medicines Control Agency as planned. |
| Response to Media Comment |
| 03/02/2003 |
|
GW notes recent media comments relating to its commercialisation discussions.
The Company has consistently stated its commercial strategy to be to enter into partnerships following Phase III trial results in order to secure optimum commercial terms. |
| GW to develop new Cannabinoid Opportunities with Professor Raphael Mechoulam |
| 22/01/2003 |
|
GW Pharmaceuticals plc, the company developing a portfolio of non-smoked, cannabis-based prescription medicines, has established an extensive research collaboration with Professor Raphael Mechoulam, from the Hebrew University of Jerusalem, Israel, one of the world’s leading cannabinoid scientists. |
| Preliminary Results for the Year Ended 30 September 2002 |
| 15/01/2003 |
|
GW Pharmaceuticals plc, the company licensed by the UK Home Office to work with cannabis and a range of controlled drugs for medical research purposes, announces its preliminary results for the year ended 30 September 2002. |
| GW Announces Positive Results From Each of Four Phase Three Clinical Trials |
| 05/11/2002 |
|
GW Pharmaceuticals plc, the company developing a portfolio of non-smoked cannabis-based prescription medicines, is today announcing preliminary results from its first four completed Phase III clinical trials. |
| Release of Positive Data from Completed Phase II Pain Trial |
| 30/09/2002 |
|
GW Pharmaceuticals plc, the pharmaceutical company developing a portfolio of non-smoked cannabis-based prescription medicines, announces the latest Phase II data from a completed 34 patient study in patients with Multiple Sclerosis (“MS”), Spinal Cord Injury and other conditions, suffering primarily from severe pain. This new data represents the largest patient study presented to date by GW and demonstrates significant benefits for patients, notably in the relief of pain and improvement in sleep. |
| GW Raises £4.5 Million In New Share Issue To Commercialise Dispensing Technology |
| 29/08/2002 |
|
GW Pharmaceuticals plc, the company licensed by the Home Office to develop prescription medicines from cannabis and other controlled drugs, announces that it has raised £4.47 million (£4.45 million net of expenses) through the issue for cash of 4,097,185 new ordinary shares (“the New Shares”). |
| Interim Results For The Six Months To 31 March 2002 |
| 13/06/2002 |
|
Dr Geoffrey Guy, Executive Chairman of GW Pharmaceuticals, said: "Progress across the breadth of the Group's activities has continued according to expectation in the first half of the financial year and GW's development programme remains firmly on track. |
| GW Expands Phase Three Clinical Trials Programme |
| 11/04/2002 |
|
GW Pharmaceuticals plc, the company developing a portfolio of non-smoked, cannabis-based prescription medicines, announces the commencement of Phase Three clinical trials in four new indications. |
| GW Pharmaceuticals plc enhances cannabinoid research activities, appoints Professor Roger Pertwee as Director of Pharmacology |
| 12/03/2002 |
|
GW Pharmaceuticals plc, the company developing a portfolio of non-smoked cannabis-based prescription medicines, announces that Professor Roger Pertwee, Professor of Neuropharmacology at the University of Aberdeen, has joined GW's senior management team as Director of Pharmacology at GW. |
| GW Welcomes Possible NHS Provision of Cannabis Based Medicines |
| 18/02/2002 |
|
GW Pharmaceuticals plc has welcomed the Government's statement that it will ask the National Institute for Clinical Excellence (NICE) to examine the possible provision of the Company's medicines by the National Health Service. |
| Annual Report & Accounts for the year ended September 2001 |
| 05/02/2002 |
|
To view this report please click here. |
| Preliminary Results for the Year Ended 30 September 2001 |
| 16/01/2002 |
|
GW Pharmaceuticals plc, the pharmaceutical company developing a portfolio of non-smoked cannabis-based prescription medicines, announces its first set of preliminary results since flotation on the Alternative Investment Market of the London Stock Exchange in June 2001. |
| GW Expands Phase Three Clinical Trials Programme of Cannabis-Based Medicine Into Cancer Pain |
| 16/01/2002 |
|
GW Pharmaceuticals plc, the company developing a portfolio of non-smoked cannabis-based prescription medicines, announces that it has expanded its Phase Three clinical trials programme into cancer pain. This Phase Three trial is the first large-scale trial of its kind and will examine the effectiveness of a cannabis-based medicine in treating pain associated with cancer. |
| GW Welcomes Home Secretary’s Statement on Cannabis-Based Medicines |
| 24/10/2001 |
|
GW Pharmaceuticals plc, the company licensed by the Home Office to develop cannabis extracts into non-smoked prescription medicines, warmly welcomes the Home Secretary's statement yesterday to the Home Affairs Select Committee. The statement confirmed that, "subject to the satisfactory outcome of phase three of the clinical trials currently being carried out, he would approve a change to the law to enable the prescription of cannabis-based medicines". |
| Appointment of Finance Director |
| 11/09/2001 |
|
GW is pleased to announce the appointment of David Kirk as Finance Director, with immediate effect. Mr Kirk succeeds Jonathan Laughton who steps down from the Board but will continue in his role of Company Secretary and becomes Financial Controller. |
| GW Releases Preliminary Data on Medicinal Cannabis Trials |
| 10/09/2001 |
|
GW Pharmaceuticals plc, the company developing a portfolio of prescription medicines derived from cannabis, today announces the first release of preliminary safety and efficacy data from its Phase One and Two clinical trials. |
| GW Pharmaceuticals Starts Medicinal Cannabis Trials in Canada |
| 14/08/2001 |
|
GW Pharmaceuticals plc, the company developing a portfolio of prescription medicines derived from cannabis, is commencing clinical trials in Canada. This is the first trial undertaken outside the United Kingdom by GW, and is believed to be the only trial of its kind in North America. |
| Clarification Re: Press Comment |
| 06/07/2001 |
|
GW Pharmaceuticals plc ("GW" or "the Company") has noted today's media coverage relating to the findings of a paper by Fiona A Campbell et al* published in the issue of the British Medical Journal ("BMJ") dated 7 July 2001, which reviews historical data from research on cannabinoids conducted between 1975 and 1997 ("the Paper"). |
| Placing and Admission to AIM |
| 21/06/2001 |
|
GW Pharmaceuticals plc ("GW" or "the Company"), a pharmaceutical company developing an innovative range of prescription medicines that harness the medicinal benefits of cannabis, announces the successful completion of the placing relating to its flotation on the Alternative Investment Market of the London Stock Exchange. |
| Publication of Pathfinder Prospectus |
| 05/06/2001 |
|
GW Pharmaceuticals plc ("GW" or "the Company"), a pharmaceutical company developing an innovative range of prescription medicines that harness the medicinal benefits of cannabis, announces that it has published a pathfinder prospectus in relation to the proposed flotation of the Company on the Alternative Investment Market of the London Stock Exchange. |
| Proposed AIM Flotation and Placing |
| 15/05/2001 |
|
GW Pharmaceuticals ("GW" or "the Company"), a pharmaceutical company developing an innovative range of prescription medicines that harness the medicinal benefits of cannabis, announces that it is planning to seek admission to the Alternative Investment Market of the London Stock Exchange. |
| GW Pharmaceuticals extends medicinal cannabis trials |
| 02/05/2001 |
|
GW Pharmaceuticals, the company licensed by the UK Home Office to undertake a pharmaceutical research and development programme to develop non-smoked cannabis-based prescription medicines, has obtained encouraging results from the latest phase of its clinical trials, and is now extending its programme into Phase Three trials, involving a wider range of patients in a number of new locations. The company has also obtained regulatory approval to commence clinical trials in Canada. |
| Medical cannabis trials to start soon in Guernsey |
| 27/08/2000 |
|
Clinical trials of cannabis-based medicines are about to start in Guernsey. Patients suffering from multiple sclerosis, chronic rheumatoid arthritis, and fibromyalgia - all conditions which are difficult to treat - will be taking part. |
| GW Pharmaceuticals to proceed with patient studies of medicinal cannabis |
| 06/04/2000 |
|
The first clinical trials of cannabis-based medicines involving patients suffering from MS, spinal cord injury and other forms of severe pain and spasticity have been given permission to proceed by the UK medical authorities. GW Pharmaceuticals, the company licensed by the UK Home Office to undertake a pharmaceutical research and development programme to develop prescription cannabis-based medicines, will commence these Phase 2 trials in the near future. |
| GW Pharmaceuticals reports progress on clinical studies with cannabis-based |
| 16/11/1999 |
|
GW Pharmaceuticals, the company licensed by the UK Home Office to undertake a pharmaceutical research and development programme to develop prescription cannabis-based medicines, has commenced its clinical programme. A Phase 1 study has been carried out in healthy volunteers using a range of non-smoked pharmaceutical drug delivery technologies. |
| GW Pharmaceuticals plans medicinal marijuana trials in Canada |
| 10/06/1999 |
|
The Canadian Government is considering a proposal from GW Pharmaceuticals to investigate the uses of non-smoked marijuana as a medicine. GW, based in the UK, has established a Canadian company which would conduct clinical trials and study delivery methods other than smoking. |
| Medicinal cannabis crop is harvested |
| 05/01/1999 |
|
The first harvest of cannabis plants is now underway at GW Pharmaceuticals, the company licensed by the Home Office to conduct a unique pharmaceutical research and development programme into the medicinal uses of cannabis. Sowing commenced in August, and the initial crop of 5,000 plants has been growing in a climate-controlled glasshouse at a secure research facility in the South of England. |
| Medicinal cannabis crop grows tall |
| 11/11/1998 |
|
The first pictures were released today by GW Pharmaceuticals, the company licensed by the Home Office to conduct a unique pharmaceutical research and development programme into the medicinal uses of cannabis.
|
| Details released of collaboration between GW Pharmaceuticals and Hortapharm medicinal cannabis |
| 23/07/1998 |
|
Details have been disclosed of the collaboration between GW Pharmaceuticals - the British Company licensed by the Home Office to conduct research into the medicinal uses of cannabis - and Dutch medicinal cannabis plant breeding company HortaPharm B.V. |
| Home Office licenses research into medical uses of cannabis |
| 11/06/1998 |
|
The Home Office has issued a licence for a British pharmaceuticals company to investigate the uses of cannabis as a medicine. |